文献速递病毒性肝炎艾滋病与性传播感染

为高风险人群整合丙型肝炎照护(HepLink):基层与社区医疗多中心可行性研究的基线数据

Integrating hepatitis C care for at-risk groups (HepLink): baseline data from a multicentre feasibility study in primary and community care.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

该研究利用HepLink多中心可行性研究的基线数据,考察四个欧洲站点在基层和社区健康服务中就诊的注射吸毒者(PWID)的HCV流行与管理情况。基线评估明确了各站点照护级联中需改进的关键环节。

要点

  • 各站点既往HCV抗体检测率65%-95%,抗体阳性者RNA检测率17%-84%。
  • 抗体或RNA阳性者中,既往专科就诊率仅6%-50%,治疗启动率仅3%-33%。
  • 基层和社区服务是改善PWID丙肝照护级联的重要场所。

核心结论

  • 四个欧洲站点基层和社区服务中PWID的HCV照护级联存在需改进的关键环节。

主要发现

  • 参与者平均年龄35岁(布加勒斯特)至51岁(伦敦),男性占71%-89%。
  • 既往HCV抗体检测率65%(布加勒斯特)至95%(都柏林),受检者中抗体阳性率78%(都柏林)至95%(布加勒斯特)。
  • 抗体阳性者中既往HCV RNA检测率17%(布加勒斯特)至84%(伦敦)。
  • 抗体或RNA阳性者中既往肝病/感染病专科就诊率6%(伦敦)至50%(都柏林),治疗启动率3%(伦敦)至33%(塞维利亚)。

临床怎么用

  • 应针对各站点照护级联的薄弱环节(如RNA检测、专科转诊和治疗启动)设计干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To examine HCV prevalence and management among people who inject drugs (PWID) attending primary care and community-based health services at four European sites using baseline data from a multicentre feasibility study of a complex intervention (HepLink). METHODS: Primary care and community-based health services in Dublin, London, Bucharest and Seville were recruited from the professional networks of the HepLink consortium. Patients were eligible to participate if aged ≥18 years, on opioid substitution treatment or at risk of HCV (i.e. injecting drug use, homeless or incarcerated), and attended the service. Data on patient demographics and prior HCV management were collected on participants at baseline. RESULTS: Twenty-nine primary care and community-based health services and 530 patients were recruited. Baseline data were collected on all participants. Participants' mean age ranged from 35 (Bucharest) to 51 years (London), with 71%-89% male. Prior lifetime HCV antibody testing ranged from 65% (Bucharest) to 95% (Dublin) and HCV antibody positivity among those who had been tested ranged from 78% (Dublin) to 95% (Bucharest). Prior lifetime HCV RNA testing among HCV antibody-positive participants ranged from 17% (Bucharest) to 84% (London). Among HCV antibody- or RNA-positive participants, prior lifetime attendance at a hepatology/infectious disease service ranged from 6% (London) to 50% (Dublin) and prior lifetime HCV treatment initiation from 3% (London) to 33% (Seville). CONCLUSIONS: Baseline assessment of the HCV cascade of care among PWID attending primary care and community-based health services at four European sites identified key aspects of the care cascade at each site that need to be improved.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Nic An Riogh E, Swan D, McCombe G, et al. Integrating hepatitis C care for at-risk groups (HepLink): baseline data from a multicentre feasibility study in primary and community care. J Antimicrob Chemother. 2019. PMID: 31782502. doi:10.1093/jac/dkz454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。